减低强度预处理造血干细胞移植治疗心功能受损系统性硬化症的长期结局
该研究评估了42例心功能受累的系统性硬化症患者接受减低强度预处理自体造血干细胞移植的长期结局。5年总生存率为75%,无进展生存率为59%。移植前使用补充氧气、B型利钠肽升高与死亡率相关,抗Scl-70抗体阳性与疾病进展相关。
要点
- 减低强度预处理自体造血干细胞移植可用于严重系统性硬化症患者。
- 移植前使用补充氧气和B型利钠肽升高提示死亡风险增加。
- 抗Scl-70抗体阳性与移植后疾病进展风险增加相关。
核心结论
- 减低强度预处理自体造血干细胞移植对严重系统性硬化症表现的患者是安全的。
- 移植前使用补充氧气、B型利钠肽升高和抗Scl-70抗体阳性是移植后不良结局的危险因素。
研究设计与样本
- 研究评估了42例依次接受减低强度预处理自体造血干细胞移植的系统性硬化症伴心脏受累参与者,在最后一名参与者治疗后5年进行。
- 进展定义为重新开始使用改善病情抗风湿药或终末器官衰竭恶化。
- 采用Kaplan-Meier法确定总生存率和无进展生存率,采用多变量Cox回归识别与总生存率或无进展生存率相关的移植前特征。
主要发现
- 所有参与者均有系统性硬化症伴心脏受累的证据,95%的参与者有间质性肺病。
- 预测用力肺活量和一氧化碳弥散量的中位百分比分别为62%和45%。
- 5年总生存率为75%(95%置信区间63%-90%),5年无进展生存率为59%(95%置信区间46%-76%)。
- 移植前使用补充氧气(风险比7.88,P<0.01)和B型利钠肽升高(每pg/mL风险比1.005,P<0.01)与死亡率相关。
- 抗Scl-70抗体阳性(风险比3.03,P=0.02)与疾病进展相关。
临床怎么用
- 对于严重系统性硬化症伴心脏受累的患者,减低强度预处理自体造血干细胞移植可作为治疗选择。
- 移植前应评估补充氧气使用、B型利钠肽水平和抗Scl-70抗体状态以进行风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: High-intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced-intensity conditioning (RIC) before AHSCT in this population remains unclear. We conducted this study to determine the long-term outcomes of RIC AHSCT in patients with SSc and cardiac involvement. METHODS: We evaluated 42 participants who sequentially underwent RIC AHSCT 5 years after the last participant was treated. Progression was defined as reinitiation of disease-modifying antirheumatic drugs or worsening end-organ failure. We determined overall survival (OS) and progression-free survival (PFS) by the Kaplan-Meier method and identified pretransplant characteristics associated with OS or PFS by multivariable Cox regression. RESULTS: All participants had evidence of SSc with cardiac involvement. Ninety-five percent of participants had interstitial lung disease. The median percent predicted forced vital capacity and diffusing capacity of the lungs for carbon monoxide was 62% and 45%, respectively. The 5-year OS was 75% (95% confidence interval [CI] 63%-90%), and 5-year PFS was 59% (95% CI 46%-76%). Pretransplant supplemental oxygen use (hazard ratio [HR] 7.88, P < 0.01) and elevated B-type natriuretic peptide (BNP; HR 1.005 per pg/mL, P < 0.01]) were associated with mortality. Anti-Scl-70 antibody positivity (HR 3.03, P = 0.02) was associated with progression. Twenty-four participants (57%) who did not use supplemental oxygen and had BNP <100 pg/mL pretransplant had a 5-year OS of 91% (95% CI 80%-100%). CONCLUSION: RIC AHSCT is safe for patients with severe manifestations from SSc. Supplemental oxygen use, elevated BNP, and anti-Scl-70 antibody positivity were risk factors for worse outcomes after RIC AHSCT.
引用
- Lean Y, Richardson C, Esposito AJ, et al. Long-Term Outcomes of Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function. Arthritis Rheumatol. 2026. PMID: 41413348. doi:10.1002/art.70031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。